Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009–2022
Chen Li,Jun Hao,Chuangshi Wang,Jie Yang,Yitian Zheng,Kuo Zhang,Wen Hui,Xiangbin Meng,Jun Gao,Wei Li,Yi-Da Tang
DOI: https://doi.org/10.2147/dddt.s409617
2023-08-04
Abstract:Chen Li, 1, &ast Jun Hao, 2, &ast Chuangshi Wang, 2 Jie Yang, 1 Yitian Zheng, 1 Kuo Zhang, 3 Wen Hui, 4 Xiangbin Meng, 1 Jun Gao, 1 Wei Li, 2 Yi-Da Tang 1, 5 1 Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, People's Republic of China; 2 Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China; 3 Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China; 4 Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China; 5 Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Li; Yi-Da Tang, Email ; Objective: The incidence rate of thyroid diseases increased worldwide. This study aims to overview the changing landscape of drug clinical trials on thyroid disease during 2009– 2022. Methods: The detailed information of thyroid disease drug trials registered on the National Medical Products Administration (NMPA) Registration and Information Disclosure Platform for Drug Clinical Studies was searched and collected. The thyroid drug clinical trials were analyzed by the characteristics, time trends, indications, and geographical distribution. Results: Sixty-five thyroid disease drug clinical trials were launched from 2009 to 2022 in China, which included 21 trials in nontumorous thyroid disease and 44 trials in thyroid carcinoma. The number of registered trials of thyroid diseases including thyroid carcinoma and nontumorous thyroid disease increased steadily from 2009 to 2020. Bioequivalence studies accounted for the largest proportion (32[49.2%]), while phase I and Phase II studies both only accounted for 18.5% (12/65). A significant difference was observed in the trials phase, and randomization between thyroid carcinoma and nontumorous thyroid disease. In terms of clinical indications and drug mechanisms, the number of trials in multi-target tyrosine kinase inhibitors for thyroid carcinoma (n=35) ranked first, followed by thyroid hormone for hypothyroidism (n=7), thyrotropin for thyroid carcinoma (n=6). Sixty-five trials were led by 36 principal investigator (PI) units, and more than 30% of PI-leading units were located in Shanghai (n=7) and Beijing (n=4). Conclusion: During the past 13 years, the development of thyroid diseases drugs trials has achieved certain progress in thyroid carcinoma, especially the molecular targeted therapy, yet the development of drug trials on nontumorous thyroid disease was very slow. Keywords: thyroid disease, thyroid carcinoma, nontumorous thyroid disease, China, drug clinical trial Thyroid diseases, including thyroid carcinoma and nontumorous thyroid disease, are prevalent diseases of the endocrine system worldwide. The incidence rates of thyroid carcinoma and nontumorous thyroid disease were significantly increased in China. 1,2 As the routine screening of thyroid function is not indicated in the present guidelines, the incidence rate of nontumorous thyroid disease may be underestimated. 3,4 For the rare terminal thyroid carcinoma which cannot be treated surgically, chemotherapy and targeted therapy is the main strategy. Thyroid hormones and calcium intake should also be taken for life to maintain endocrine homeostasis in patients after thyroidectomy or with radioiodine treatment for hyperthyroidism, autoimmune thyroid disease, congenital hypothyroidism or toxic goiter. In terms of nontumorous thyroid diseases, drug therapy is the only option. The development of drug clinical trials for thyroid disease is important for the optimization of clinical therapy strategies and improvement in patients' prognosis and long-term quality of life. The National Medical Products Administration (NMPA) established a Registration and Information Disclosure Platform for Drug Clinical Studies in 2013 and required all the clinical trials conducted in China and approved by the NMPA should be registered and dis -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal